Maze Therapeutics, Inc. (MAZE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

SA Transcripts 162.16K Followers Follow Maze Therapeutics, Inc. ( MAZE ) Citigroup's Biopharma Back to School Summit 2026 September 10, 2026 2:20 PM EDT Company Participants Misbah Tahir - CFO & Principal Accounting Officer Conference Call Participants Eric Joseph - Citigroup Inc., Research Division Presentation Eric Joseph Citigroup Inc., Research Division Yes. Welcome to Day 2 of Citi's Back to School Biopharma Conference. I'm Eric Joseph, Senior Biotech Analyst with the firm. And our session now is with Maze Therapeutics. It's my pleasure to have with us CFO, Misbah Tahir, to talk to us about the company. Misbah, thanks for joining us today. Maybe just for those less familiar with the company on the webcast, it would be useful to have you kind of provide us with a brief snapshot of the company and what some of Maze's key objectives are over the next 12 to 18 months. Misbah Tahir CFO & Principal Accounting Officer Eric, it's great to see you again, and I'm excited to represent Maze this afternoon. Just some background on Maze Therapeutics. We're a clinical-stage biopharmaceutical company focused on developing precision medicines for kidney and metabolic diseases. We have 3 programs in clinical development. Our lead program is MZE829. That's an APOL1 inhibitor for the treatment of patients who suffer from APOL1-mediated kidney disease, or AMKD. We're currently in a Phase II trial testing MZE829 in AMKD patients, and we've guided to data from this study, which we refer to as HORIZON, by the end of this year or early next year. We've also committed to initiating a pivotal program with MZE829 in the first half of 2027. Our second program is MZE782. That's an inhibitor of SLC6A19, a transporter of neutral amino acids. And we just announced last month that we initiated our Phase II study of MZE782 for the treatment of patients with